Infliximab 5 mg/kg and purine analogues vs purine analogues
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 0.87 [0.63, 1.21]4 studies · 603 participantsLow